BRD4 restores anti-tumor immune responses following chemical inhibition with small-molecule bromodomain inhibitor JQ1, by down regulating PD-L1 expression in a MYC dependent manner in multiple myeloma [134]. Here, BRD4 is linked to neoplasm.